CEACAM5 and hepatocellular carcinoma: A transient increase in the serum CEA and CA15-3 may occur in patients with metastatic breast cancer that are receiving systemic chemotherapy [46], and similar surges of serum biomarkers have been demonstrated in patients with a hepatocellular carcinoma regarding α-fetoprotein [47], in patients with a testicular germ cell tumour with human chorionic gonadotropin [48], and in patients with metastatic gastric cancer with CEA and CA19-9 [49], mostly predicting the clinical benefits of chemotherapy.